McKesson Research and Development Expenses 2010-2024 | MCK

McKesson annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • McKesson research and development expenses for the quarter ending June 30, 2024 were $M, a NAN% increase year-over-year.
  • McKesson research and development expenses for the twelve months ending June 30, 2024 were $0M, a NAN% increase year-over-year.
  • McKesson annual research and development expenses for 2024 were $0B, a NAN% decline from 2023.
  • McKesson annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • McKesson annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
McKesson Annual Research and Development Expenses
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $125
2017 $341
2016 $392
2015 $392
2014 $457
2013 $433
2012 $402
2011 $407
2010 $376
2009 $364
McKesson Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $78.143B $308.951B
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $67.812B 17.83
Cardinal Health (CAH) United States $29.438B 15.96
West Pharmaceutical Services (WST) United States $23.723B 48.46
Cooper (COO) United States $20.623B 29.35
Labcorp (LH) United States $20.401B 16.92
Align Technology (ALGN) United States $16.815B 32.18
Henry Schein (HSIC) United States $8.514B 16.22
Merit Medical Systems (MMSI) United States $6.067B 30.98
DENTSPLY SIRONA (XRAY) United States $3.508B 9.54
CONMED (CNMD) United States $2.312B 19.29
Patterson (PDCO) United States $1.855B 9.79
STAAR Surgical (STAA) United States $1.499B 55.31
Lifevantage (LFVN) United States $0.176B 23.40
Pro-Dex (PDEX) United States $0.154B 30.74